• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

联合α和β肾上腺素能阻滞剂(拉贝洛尔)对血压正常、患有稳定型心绞痛且运动应激试验反应阳性患者的全身及冠状动脉血流动力学影响。

Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses.

作者信息

Prida X E, Hill J A, Feldman R L

出版信息

Am J Cardiol. 1987 May 1;59(12):1084-8. doi: 10.1016/0002-9149(87)90853-8.

DOI:10.1016/0002-9149(87)90853-8
PMID:2883869
Abstract

The systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade produced by labetalol were assessed in 12 normotensive patients with angina pectoris and an ischemic electrocardiographic response to exercise stress. When given to the patient at rest, labetalol (0.5 mg/kg intravenously) produced systemic and coronary vasodilation (mean 16% and 13%, respectively, both p less than 0.05); aortic pressure decreased, cardiac output increased and coronary flow and heart rate did not change. Before labetalol treatment, supine bicycle exercise produced angina in all patients. After treatment, exercise duration was prolonged in 8 patients (average 33%). At the same duration of exercise that led to angina during the control period, ST depression in lead V5 was less after labetalol (from 1.2 to 0.4 mm, p less than 0.5). During exercise, tachycardia was blunted (-12%, p less than 0.05) as were the increases in aortic pressure (-12%, p less than 0.05), left ventricular end-diastolic pressure (-7%, difference not significant) and coronary sinus flow (-16%, p less than 0.05). Cardiac output and systemic and coronary vascular resistance were similar to values during control exercise. The hemodynamic effects of labetalol appeared to be beneficial and differed from those of classic beta-adrenergic blocking agents.

摘要

在12例血压正常、患有心绞痛且运动应激时心电图有缺血反应的患者中,评估了拉贝洛尔联合α和β肾上腺素能阻滞产生的全身和冠状动脉血流动力学效应。静息状态下给患者静脉注射拉贝洛尔(0.5mg/kg)后,出现全身和冠状动脉血管舒张(分别平均为16%和13%,p均小于0.05);主动脉压下降,心输出量增加,冠状动脉血流和心率未改变。在拉贝洛尔治疗前,所有患者仰卧位骑单车运动均诱发心绞痛。治疗后,8例患者运动持续时间延长(平均33%)。在对照期导致心绞痛的相同运动持续时间时,拉贝洛尔治疗后V5导联ST段压低减轻(从1.2mm降至0.4mm,p小于0.5)。运动期间,心动过速受到抑制(-12%,p小于0.05),主动脉压升高(-12%,p小于0.05)、左心室舒张末期压力升高(-7%,差异无统计学意义)和冠状窦血流增加(-16%,p小于0.05)也受到抑制。心输出量以及全身和冠状动脉血管阻力与对照运动期间的值相似。拉贝洛尔的血流动力学效应似乎是有益的,且与经典的β肾上腺素能阻滞剂不同。

相似文献

1
Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses.联合α和β肾上腺素能阻滞剂(拉贝洛尔)对血压正常、患有稳定型心绞痛且运动应激试验反应阳性患者的全身及冠状动脉血流动力学影响。
Am J Cardiol. 1987 May 1;59(12):1084-8. doi: 10.1016/0002-9149(87)90853-8.
2
Systemic and coronary hemodynamic effects of combined oral alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress tests.联合口服α和β肾上腺素能阻滞剂(拉贝洛尔)对血压正常、患有稳定型心绞痛且运动应激试验阳性患者的全身和冠状动脉血流动力学影响。
Clin Cardiol. 1988 Jun;11(6):383-8. doi: 10.1002/clc.4960110605.
3
Systemic and coronary hemodynamics of labetalol in normotensive patients with ischemic heart disease.拉贝洛尔对患有缺血性心脏病的血压正常患者的全身及冠状动脉血流动力学影响
Cardiovasc Drugs Ther. 1988 Sep;2(3):355-61. doi: 10.1007/BF00054643.
4
Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.α-β受体联合阻滞的药理学。II. 拉贝洛尔的血流动力学效应。
Drugs. 1984;28 Suppl 2:35-50. doi: 10.2165/00003495-198400282-00004.
5
Alpha- and beta-blockade in angina pectoris.心绞痛中的α和β受体阻滞剂
Drugs. 1984;28 Suppl 2:69-87. doi: 10.2165/00003495-198400282-00006.
6
Differential hemodynamic effects of beta-adrenoceptor blockers, Ca antagonists and combined alpha-beta-receptor blockade in ischemic heart disease.β-肾上腺素能受体阻滞剂、钙拮抗剂及α-β受体联合阻滞对缺血性心脏病的不同血流动力学效应
Acta Med Scand. 1986;219(1):17-22. doi: 10.1111/j.0954-6820.1986.tb03270.x.
7
Comparison of selective (beta 1) and nonselective (beta 1 and beta 2) beta-adrenergic blockade on systemic and coronary hemodynamic findings in angina pectoris.选择性(β1)与非选择性(β1和β2)β-肾上腺素能阻滞剂对心绞痛患者全身及冠状动脉血流动力学影响的比较。
Am J Cardiol. 1987 Aug 1;60(4):244-8. doi: 10.1016/0002-9149(87)90221-9.
8
Hemodynamic effects at rest and during exercise of combined alpha/beta-receptor blockade and of beta-receptor blockade alone in patients with ischemic heart disease.缺血性心脏病患者静息及运动时联合α/β受体阻滞剂与单独使用β受体阻滞剂的血流动力学效应。
J Cardiovasc Pharmacol. 1987 Oct;10(4):474-8. doi: 10.1097/00005344-198710000-00014.
9
Acute effects of combined alpha/beta-adrenoceptor blockade v combined beta-receptor and slow channel calcium blockade in ischemic heart disease complicated by hypertension. Hemodynamic and adrenergic responses.α/β肾上腺素能受体联合阻滞与β受体及慢通道钙阻滞对合并高血压的缺血性心脏病的急性影响。血流动力学及肾上腺素能反应。
Am J Hypertens. 1991 Aug;4(8):709-13. doi: 10.1093/ajh/4.8.709.
10
Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.静脉注射拉贝洛尔后,α和β肾上腺素能受体联合阻断对高血压患者静息及运动时血流动力学的影响。
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):725-8.

引用本文的文献

1
Systemic and coronary hemodynamics of labetalol in normotensive patients with ischemic heart disease.拉贝洛尔对患有缺血性心脏病的血压正常患者的全身及冠状动脉血流动力学影响
Cardiovasc Drugs Ther. 1988 Sep;2(3):355-61. doi: 10.1007/BF00054643.
2
Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.血管舒张在拉贝洛尔降压及抗心绞痛作用中的作用:对合并高血压和心绞痛治疗的启示
Cardiovasc Drugs Ther. 1988 Sep;2(3):369-76. doi: 10.1007/BF00054645.
3
Labetalol in normotensive patients with angina pectoris.
拉贝洛尔用于患心绞痛的血压正常患者。
Cardiovasc Drugs Ther. 1988 Sep;2(3):363-7. doi: 10.1007/BF00054644.
4
Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.拉贝洛尔(一种兼具α和β受体阻滞作用的药物)与心肌缺血治疗相关的特性。
Cardiovasc Drugs Ther. 1988 Sep;2(3):343-53. doi: 10.1007/BF00054642.